Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168488 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL4170645 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL30147114 | 1.00 | TAAR1 (0.70) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL14199081 | 0.89 | TAAR1 (0.56) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL27494557 | 0.87 | SLC6A3 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL25200234 | 0.86 | CYP3A4 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL19342841 | 0.86 | TAAR1 (0.66) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| SCHEMBL25190561 | 0.86 | CYP3A4 (0.55) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| Machilin A SCHEMBL30678762 | 0.85 | TAAR1 (0.74) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 | |
| Machilin A SCHEMBL31237868 | 0.85 | TAAR1 (0.74) | TAAR1SLC6A4SLC6A2SLC6A3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240010628-A1 | METHODS OF MANUFACTURE OF R-MDMA | Mind Medicine, Inc. (US) | 2024-01-11 | — | — | US | claimed |
| CN-102617543-A | Synthesis methods for piperonyl ethanol and derivatives thereof | UNIV TIANJIN SCIENCE & TECH | 2012-08-01 | — | — | CN | claimed |
| US-6160133-A | Synthesis of (S)-α-methyl-1,3-benzodioxole-5-ethanol and derivatives | ELI LILLY AND COMPANY (US) | 2000-12-12 | — | — | US | claimed |
| US-12600708-B2 | Prodrug compounds of 3,4-methylenedioxymethamphetamine (MDMA) and methods of synthesizing the same | APOAPSIS HOLDINGS, LLC (US) | 2026-04-14 | — | — | US | disclosed |
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | APOAPSIS HOLDINGS, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4583865-A1 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | Mydecine Innovations Group Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20240400526-A9 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | MYDECINE INNOVATIONS GROUP INC (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2024-06-20 | — | — | US | disclosed |
| US-20240092747-A1 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | Altrartis Therapeutics Inc. | 2024-03-21 | — | — | US | disclosed |
| WO-2024054279-A1 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-1123282-A | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives | LILLY CO ELI (US) | 1996-05-29 | — | — | CN | disclosed |
| WO-1996006606-A1 | DIHYDRO-2,3-BENZODIAZEPINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-03-07 | — | — | WO | disclosed |
| EP-0699678-A1 | Crystalline form of dihydro-2,3-benzodiazepine derivative | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0699676-A1 | Physical form of dihidro-2,3-benzodiazepine derivative | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0699677-A1 | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives | ELI LILLY AND COMPANY (US) | 1996-03-06 | — | — | EP | disclosed |
| CN-86100669-A | The synthetic organic polymers that is used for selective flocculating floatation of titanium and iron ores | — | 1987-08-05 | — | — | CN | disclosed |
| EP-0004929-B1 | INSECTICIDAL AND ACARICIDAL COMPOSITIONS COMPRISING ISOCHROMAN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BAYER AG (DE) | 1981-04-08 | — | — | EP | disclosed |
| US-4247560-A | 6,7-Methylenedioxy-isochromane arthropodicide synergizing agents | BAYER AKTIENGESELLSCHAFT (DE) | 1981-01-27 | — | — | US | disclosed |
| EP-0004929-A2 | Insecticidal and acaricidal compositions comprising isochroman derivatives, process for their preparation and application | BAYER AG (DE) | 1979-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570621-B2 | Short-acting 3,4-methylenedioxymethamphetamine (MDMA) analogs incorporating benzothiazole | SLC6A3, SLC6A2, HTR2C | TAAR1 20/4885SLC6A4 21/4885SLC6A2 2/4885 |
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | PNMT, HTR2C, SLC18A2 | TAAR1 24/4885SLC6A4 10/4885SLC6A2 16/4885 |
| US-12600708-B2 | Prodrug compounds of 3,4-methylenedioxymethamphetamine (MDMA) and methods of synthesizing the same | OPRM1, DRD3, SLC6A3 | TAAR1 39/4885SLC6A4 28/4885SLC6A2 16/4885 |
| US-20240400526-A9 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | HTR3B, HTR3C, HTR3E | TAAR1 39/4885SLC6A4 16/4885SLC6A2 24/4885 |
| US-20240092747-A1 | SHORT-ACTING 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) ANALOGS INCORPORATING BENZOTHIAZOLE | HTR3B, HTR3C, HTR3E | TAAR1 39/4885SLC6A4 16/4885SLC6A2 24/4885 |
| US-12569466-B2 | Short-acting psychoactive compounds of the MDMA class | HTR2C, SLC6A2, DRD2 | TAAR1 31/4885SLC6A4 10/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.